A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors

Prior treatment

• Use of anticancer agents within specified intervals prior to the first dose of study drug.
• Had surgery, chemoembolization, or radiofrequency ablation within 90 days prior to first dose of study drug.
• Prior participation in any intervention clinical study within 30 days or 5 half-lives (whichever is longer) prior to the first dose of study drug.
• Have prior treatment with MMAE.

Other illness

• Participants with carcinoid syndrome.
• Secondary malignancy: participants who have any other malignancy known to be active or treated within 3 years of the start of screening, with the exception of treated cervical intraepithelial neoplasia, superficial (noninvasive) bladder cancer, and non-melanoma skin cancer.
• Have hypersensitivity or history of anaphylactic reaction to octreotide, other SSAs, and/or MMAE.

Other

• Have tumor progression while undergoing a course of PRRT or within 6 months of completing PRRT.
• Have brain metastases unless asymptomatic and stable for at least one month for participants with SCLC or LCLC or at least 3 months for participants with other non-NET solid tumors.

• Have a histological diagnosis of metastatic or locally advanced inoperable NET, NEC, or other solid tumors that have confirmed radiological progression.
• Have one or more measurable disease location per RECIST version 1.1.
• Have a tumor that expresses SSR confirmed by SSR imaging.
• Have an ECOG performance status of 0, 1, or 2.